Bluebird Bio, Inc. Announces Resignation of Wendy L. Dixon as Director, and Its Audit Committee and Compensation Committee
November 23, 2021 at 04:47 pm EST
Share
On November 23, 2021, Wendy L. Dixon, Ph.D. notified bluebird bio, Inc.of her resignation as a director from the Company?s Board of Directors, and its Audit Committee and Compensation Committee, effective immediately. Dr. Dixon?s resignation was not caused by any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
BLUEBIRD BIO, INC. 
